Conduit Pharmaceuticals Stock Analysis
| CDT Stock | 2.14 0.04 1.90% |
Conduit Pharmaceuticals is fairly valued with Real Value of 2.05 and Hype Value of 1.85. The main objective of Conduit Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Conduit Pharmaceuticals is worth, separate from its market price. There are two main types of Conduit Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Conduit Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Conduit Pharmaceuticals is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Conduit Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Conduit Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. Conduit Stock Analysis Notes
About 18.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.89. Some equities with similar Price to Book (P/B) outperform the market in the long run. Conduit Pharmaceuticals recorded a loss per share of 255.6. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 20th of May 2025. For more info on Conduit Pharmaceuticals please contact Andrew Regan at (646)-491-9132 or go to https://www.conduitpharma.com.Conduit Pharmaceuticals Investment Alerts
| Conduit Pharmaceuticals generated a negative expected return over the last 90 days | |
| Conduit Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 922.22 M. Reported Net Loss for the year was (17.8 M) with profit before taxes, overhead, and interest of 0. | |
| Conduit Pharmaceuticals generates negative cash flow from operations | |
| Conduit Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| About 18.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Is Conduit Pharmaceuticals Inc. a good long term investment - Skyrocketing profit margins - jammulinksnews.com |
Conduit Pharmaceuticals Upcoming and Recent Events
| 19th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Conduit Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Conduit Pharmaceuticals' ESG score is a quantitative measure that evaluates Conduit Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Conduit Pharmaceuticals' operations that may have significant financial implications and affect Conduit Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Conduit Market Capitalization
The company currently falls under 'Nano-Cap' category with a total capitalization of 5.07 M.Conduit Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (40.69) | (38.66) | |
| Return On Assets | 47.32 | 49.69 | |
| Return On Equity | (29.21) | (27.75) |
Management Efficiency
Conduit Pharmaceuticals has Return on Asset of (1.6826) % which means that on every $100 spent on assets, it lost $1.6826. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 49.69 in 2025, whereas Return On Tangible Assets are likely to drop (0.15) in 2025. Total Current Liabilities is likely to gain to about 11.3 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 3.2 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.17) | (0.18) | |
| Tangible Book Value Per Share | (35.50) | (33.72) | |
| Enterprise Value Over EBITDA | 15.74 | 16.53 | |
| Price Book Value Ratio | (616.43) | (647.25) | |
| Enterprise Value Multiple | 15.74 | 16.53 | |
| Price Fair Value | (616.43) | (647.25) |
Management at Conduit Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Technical Drivers
As of the 22nd of July, Conduit Pharmaceuticals shows the Mean Deviation of 5.05, standard deviation of 7.23, and Risk Adjusted Performance of (0.31). Conduit Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Conduit Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Conduit Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Conduit Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles.
Conduit Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Conduit Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Conduit Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Conduit Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Conduit Pharmaceuticals Outstanding Bonds
Conduit Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Conduit Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Conduit bonds can be classified according to their maturity, which is the date when Conduit Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| US20679LAB71 Corp BondUS20679LAB71 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Conduit Pharmaceuticals Predictive Daily Indicators
Conduit Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Conduit Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Conduit Pharmaceuticals Forecast Models
Conduit Pharmaceuticals' time-series forecasting models are one of many Conduit Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Conduit Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Conduit Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Conduit Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Conduit shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Conduit Pharmaceuticals. By using and applying Conduit Stock analysis, traders can create a robust methodology for identifying Conduit entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.22 | 0.20 | |
| Operating Profit Margin | 0.26 | 0.23 | |
| Net Profit Margin | 0.19 | 0.18 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Conduit Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.